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Abstract: Purpose of Review: This is a comprehensive review of the literature regarding the use of
paliperidone in the treatment of schizophrenia and schizoaffective disorder. It covers the background
and presentation of schizophrenia and schizoaffective disorder, as well as the mechanism of action
and drug information for paliperidone. It covers the existing evidence of the use of paliperidone for
the treatment of schizophrenia and schizoaffective disorder. Recent Findings: Schizophrenia and
schizoaffective disorder lead to significant cognitive impairment. It is thought that dopamine dysreg-
ulation is the culprit for the positive symptoms of schizophrenia and schizoaffective disorder. Similar
to other second-generation antipsychotics, paliperidone has affinity for dopamine D2 and serotonin
5-HT2A receptors. Paliperidone was granted approval in the United States in 2006 to be used in the
treatment of schizophrenia and in 2009 for schizoaffective disorder. Summary: Schizophrenia and
schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and nega-
tive symptoms. Patients with either of these mental illnesses suffer from impairments in everyday
life. Paliperidone has been shown to reduce symptoms of schizophrenia and schizoaffective disorder.
Keywords: paliperidone palmitate; antipsychotic agents; psychotic disorders; family characteristics;
cognitive dysfunction; dopamine; serotonin
1. Introduction
Schizophrenia and schizoaffective disorder are two mental illnesses that have a deep
impact on both their affected populations as well as our society as a whole. Multiple genetic
and environmental factors contribute to the development of both disorders, leaving much
of their etiology unknown [1]. The triad of schizophrenia includes cognitive impairment,
positive symptoms and negative symptoms [2]. Drawing a fine line between this and
schizoaffective disorder is rather difficult [3]. It is believed that schizoaffective disorder
lies in the middle of the spectrum between schizophrenia and bipolar disorder, sharing
characteristic symptoms of both [4]. Nonetheless, patients with either illness suffer great
impairments to their everyday lives. Several studies have demonstrated that patients with
schizophrenia or schizoaffective disorder experience similar social deficits in addition to a
lower IQ when compared to control groups [4,5]. According to Charlson et al., “Despite
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being a low prevalence disorder, schizophrenia ranked the 12th most disabling disorder
among 310 diseases and injuries globally” [6]. It is estimated that unemployment rates
run around 80–90% in schizophrenia patients and life expectancy is decreased 14.5 years
on average [2,6]. Numerous factors contribute to the early mortality rate, with one of the
main causes being the higher incidence of comorbid health conditions in schizophrenia
patients [6]. A second major contributing factor is the increased lifetime suicide rate, which
is estimated to be around 10% in this population [7]. The only known way to decrease this
risk is through compliance with treatment [7].
Although there is much undiscovered about the exact pathophysiology of these
disorders, what is evident is the severe economic burden they bring to our society [2]. The
estimated expense for schizophrenia in the United States in 2013 was USD 155.7 billion [8].
This included the cost for direct healthcare, direct non-healthcare (mainly unemployment
and caregiving) and indirect costs [8]. Schizophrenia patients between the ages of 25 and
54 bring on the bulk of the economic burden as this age range is when individuals are
typically the most economically productive [6]. Their high unemployment rate leads to
serious economic losses not only from the under-productivity of the patient but additionally
from the under-productivity of the family [6]. Family members frequently have to care
for the patient at home and pay for treatment. This combination results in considerable
deficits in the health and welfare systems [6].
Together, these factors demonstrate a real need to find more effective treatments for
these disorders. There are approximately 21 million people globally living with schizophre-
nia whose lives are hindered by the course of this illness [6]. Finding a treatment that
patients will not only comply with but that has minimal side effects could drastically
improve their individual lives, as well as relieve some of the societal burdens that accom-
pany these illnesses. It has been suggested that current antipsychotic treatment might also
contribute to the increased risk of suicide in patients, further strengthening our objective to
find a better treatment course [6]. The aim of this article is to give a compiled overview
of the drug paliperidone for the treatment of schizophrenia and schizoaffective disorder
through exploring its pharmacological properties and clinical safety/efficacy.
2. Schizophrenia and Schizoaffective Disorder
2.1. Epidemiology
Schizophrenia and schizoaffective disorder share a very similar epidemiology, patho-
physiology and presenting symptoms. However, there are some differences between them.
The point prevalence of both disorders is low with schizophrenia being estimated at 0.28%
and schizoaffective disorder at 0.11% [6,9]. Differences in prevalence among genders varies
with studies. Some found that both schizophrenia and schizoaffective disorder had an
equal distribution between sexes [6,10]. If a gender difference was found, it was trending
towards schizophrenia being slightly more prevalent in males and schizoaffective disorder
being slightly more prevalent in females [11,12].
Multiple studies have implicated the role of genetic abnormalities being a contributing
factor for the development of schizophrenia ranging from polymorphisms in single genetic
loci to copy number variants (CNVs) [1,2]. Hundreds to thousands of specific loci have
been identified that are thought to contribute to the risk of developing schizophrenia [1,2].
Additionally, less frequent but high risk CNVs on genes encoding voltage-gated calcium
channels, glutamate and dopamine receptors and components of post-synaptic density
have been implicated as risk factors [2]. Despite the compelling evidence supporting these
genetic differences in the etiopathogenesis of schizophrenia, no one single genetic variation
is exclusively specific, making them non-diagnostic [1]. There is little research on the
specific genetics of schizoaffective disorder. Nonetheless, based on similar heritability
estimates and risk factors, it is very likely that schizoaffective disorder shares some of the
genetic variants found in schizophrenia [10,12].
In addition to genetic changes, other studies have demonstrated environmental rela-
tionships. Multiple groups have found that individuals being born during the winter/early
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spring months are at an increased risk for developing schizophrenia [13,14]. Individuals
living in urbanized areas have also been demonstrated by multiple studies to have a con-
siderably increased risk of developing schizophrenia and schizoaffective disorder [2,10,15].
Both of these increased risks have been proposed to possibly be the result of either in utero
infection and/or other environmental exposures of the fetus [15]. Seasonal variation, as
well as the high population in urban areas, could also be contributing factors to either
susceptibility circumstance [15]. More recent evidence has been found to support the
association between cannabis use and an increased risk of psychotic illness, including but
not limited to schizophrenia and schizoaffective disorder [16,17]. A strong association
with schizoaffective patients and a family history of affective disorders has also been
affirmed [18].
As previously mentioned, although there are several risk factors leading to increased
susceptibility of developing schizophrenia and schizoaffective disorders, no one factor
is solely responsible [15]. These illnesses are highly polygenic and depend on a diverse
interaction between the environment, psychology and social surroundings individual to
each patient [15].
2.2. Pathophysiology
Dopamine dysregulation is one of the most widely accepted pathophysiological pro-
cesses leading to the positive symptoms seen in schizophrenia [2]. The basis of this belief
stems from the fact that schizophrenia patients seem to have a hypersensitivity to dopamine-
like drugs, giving them enhanced symptoms such as delusions and hallucinations when
compared to control groups [2,19]. This is additionally supported by evidence that current
treatment with antipsychotics that block dopamine receptors sufficiently reduce hallu-
cinations and delusions seen in these patients [1]. While it is clear that dopaminergic
dysfunction plays a large role in the genesis of both schizophrenia and schizoaffective
disorder, it is not the only factor responsible [20]. Abnormalities of glutamatergic function
have also been implicated for contributing to the disturbances seen in these disorders [21].
Evidence from multiple studies investigating genetics, imaging, NMDA receptor (NMDAR)
antagonists and treatments that increase NMDAR function in schizophrenia patients all
support the notion of NMDAR hypofunction contributing to symptoms [22].
Multiple studies researching brain imaging identified that both schizophrenia and
schizoaffective disorder patients had reduced grey matter volume [2,5,23]. Although these
reductions were found to be more drastic in schizophrenia patients, schizoaffective patients
still showed remarkable similarity with regards to having volume reductions in the same
cortical areas as schizophrenia patients [5]. Both groups displayed grey matter reductions
in the temporal lobe, medial frontal cortex, insula, hippocampus and cerebellum [5]. The
grey matter reduction is progressive throughout the course of the illnesses, with notable
activity affecting the left hemisphere and temporal lobe during the early stages [24].
2.3. Clinical Presentation
Schizophrenia and schizoaffective disorder share many of the same presenting symp-
toms, but they differ in their severity leading to a considerably better prognosis in schizoaf-
fective disorder [3]. Both typically present in early adulthood and are characterized by
complex psychopathology [2,6,11]. The main features of schizophrenia are positive symp-
toms, negative symptoms and cognitive impairment [2,25]. Positive symptoms consist of
hallucinations, delusions and disorganized speech, while negative symptoms are character-
istically reduced emotional expression, social withdrawal and impaired motivation [2,15].
The diminished cognitive functions experienced by patients include deficits in working
memory and executive function, although there is “significant cognitive heterogeneity”
among individuals [2,26].
In contrast, schizoaffective disorder is a much less stable diagnosis with much debate
among clinicians and researchers [3]. According to DSM 5, schizoaffective disorder is
diagnosed based on the following four criteria [27]. Criterion A states the patient must
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experience symptoms of psychosis from criterion A of schizophrenia simultaneously with
a major mood episode (manic or depressive) [27]. Criterion B requires two or more weeks
of hallucinations or delusions in the absence of a major mood episode [27]. Criterion C
states symptoms of a major mood episode must be “present for the majority of the total
duration of the active and residual portions of the illness” [27]. Moreover, lastly, criterion D
is the acknowledgment that none of the aforementioned disturbances are a result of another
condition or substance use [27]. Much of the controversy with schizoaffective disorder
is over the fact that it is described as an intermediate disorder between schizophrenia
and bipolar disorder [3]. Several studies assessing cognitive functions and neuroimaging
found schizoaffective disorder resembles schizophrenia significantly more than bipolar
disorder [3,5,23]. IQ deficits and presenting symptoms (positive, negative and cognitive
impairment) among schizophrenia and schizoaffective disorder were not different from
each other but were found to be significantly different from the bipolar patients [3,5].
Additionally, brain imaging is consistent with schizoaffective disorder being more skewed
towards schizophrenia than bipolar disorder [5].
3. Current Treatment of Schizophrenia and Schizoaffective Disorder
While dementia praecox, meaning premature dementia, was first described in 1887 by
Emil Kraepelin [28], this was later redescribed by Eugen Bleuler as schizophrenia. Pharmaco-
logical treatment was not utilized until the 1950s, when chlorpromazine was synthesized [29].
The main pharmacologic treatment for schizophrenia and schizoaffective disorder is broken
down into first-generation, second-generation and third-generation antipsychotics.
First-generation antipsychotics, also known as typical antipsychotics, work mainly by
blocking the D2 receptors in the brain, affecting the positive symptoms (e.g., hallucinations
and thought disorders) of schizophrenia. These typical antipsychotics do not selectively
block the D2 dopamine receptors and can therefore have a wide range of side effects. Typical
antipsychotics are further divided into high potency and low potency. The classification
into high potency and low potency is based on “chlorpromazine equivalence,” where
haloperidol and fluphenazine are categorized as high potency and thioridazine is low
potency, making it comparable with chlorpromazine. High potency antipsychotics are
more likely to cause extrapyramidal symptoms (EPS) than low potency antipsychotics [29].
Second-generation antipsychotics, also known as atypical antipsychotics, are D2 and
5HT2A receptor antagonists. Studies have shown that 75–87% of patients presenting with
first-episode psychosis respond to primary antipsychotic therapy within four weeks to one
year [30–33]. Clozapine, the first FDA approved drug for treatment-resistant schizophrenia,
was the catalyst to the discovery of the second-generation antipsychotics [34,35]. While it
was the first drug of its class, it doesn’t come without its many side effects. Many physicians
will avoid using clozapine prior to the failure of other drug combinations due to the five
black box warnings associated with the usage of the clozapine. Some risks included are
agranulocytosis, orthostatic hypotension, myocarditis and seizures.
Third generation antipsychotics are the newest group and have been individualized
based on their mechanism of action at dopamine receptors. Unlike the first- and second-
generation antagonists, the third generations act as partial agonists at the D2 receptors [29].
Cariprazine, approved in 2015, is a partial agonist at the D2, D3 and 5-HT1A receptors, with
an affinity 10 times higher for the D3 receptor than the D2 receptor. This affinity has made
this drug especially useful for the treatment of schizophrenia with dominant negative
symptoms, a classically difficult to treat subset of patients [36].
Side effects of antipsychotics include EPS (e.g., dystonia, akathisia, parkinsonism),
increased risk of neuroleptic malignant syndrome, weight gain, hyperprolactinemia and
sedation [37]. These side effects are what guide a clinician to use one drug over another, as
Huhn et al. found that efficacy differences between the antipsychotics are mostly gradual
rather than discrete, while the side effect differences are more marked [37].
While treatment of schizophrenia and schizoaffective disorder remains anchored in
pharmacologic therapy, non-pharmacological adjunctive treatments have proven to be ef-
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fective. It has been shown that patients with less than six months duration of antipsychotic
treatment who were enrolled in the model program NAVIGATE reported lower PANSS
scores were more likely to remain in treatment, enjoy a better quality of life and participate
more in work/school than usual care [38,39]. Patients with treatment-resistant schizophre-
nia can also benefit from non-pharmacologic modalities, such as cognitive behavioral
therapy for psychosis, hallucination focused integrative therapy, repetitive transcranial
magnetic stimulation and electroconvulsive therapy [40–45].
Schizoaffective Disorder
Schizoaffective disorder can be more difficult to diagnose, making it harder to study
and, therefore, leaving it with far fewer FDA approved drug treatments. Currently, only
paliperidone extended-release (ER) and long-acting injectable (LAI) forms, along with
risperidone, have been shown to be effective in the treatment of schizoaffective disorder [46].
This is not surprising, considering paliperidone is an active metabolite of risperidone [46].
Most of the evidence provided for the treatment of this disorder is through indirect evidence,
mainly from studies in patients with schizophrenia [47]. The only schizoaffective disorder
specific studies with a large sample size were those conducted for paliperidone, which is
how the drug got FDA approval for the treatment of this disorder [46].
4. Paliperidone Drug Info
Paliperidone is an atypical antipsychotic that is a major active metabolite of risperi-
done (5-hydroxyrisperidone), approved for use in the US in 2006 as daily oral extended-
release tablets and 1-month or 3-month LAI formulations [48–50]. Paliperidone ER is
indicated for treatment of schizophrenia in adults and adolescents ages 12–17 [48]. It is
available in 1.5 mg, 3 mg, 6 mg, 9 mg and 12 mg [48]. The LAI form of paliperidone
is indicated for the treatment of schizophrenia or schizoaffective disorder in adults as
monotherapy or in conjunction with mood stabilizers, only after tolerance to oral paliperi-
done or risperidone has been demonstrated [49,50]. The 3-month injectable is to be used
only after successful administration of the 1-month LAI [50]. The 1-month LAI is avail-
able in dosages of 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg and the 3-month injectable
is available in the higher dosages of 273 mg, 410 mg, 546 mg, or 819 mg [49,50]. Con-
traindications to the use of paliperidone include previous hypersensitivity reactions to
paliperidone or risperidone [48–50]. Paliperidone, like all antipsychotics, is contraindicated
for use in elderly patients with dementia-related psychosis, holding a boxed warning
for increased mortality in this population [48–50]. Adverse events of paliperidone are
consistent with other atypical antipsychotics due to dopamine blockade and effects at
other neurotransmitter receptors. These include cerebrovascular disease (in the elderly),
neuroleptic malignant syndrome, QT prolongation, extrapyramidal symptoms, tardive
dyskinesia, weight gain, dyslipidemia, hyperglycemia, hyperprolactinemia, orthostatic
hypotension, leukopenia, cognitive impairment and seizures [48–50]. No teratogenic effects
have been demonstrated, but there is increased risk for EPS and/or withdrawal symptoms
in neonates exposed during pregnancy [48–50]. Coadministration of paliperidone ER
tablets or LAI with risperidone has not been studied [48–50].
5. Mechanism of Action
Paliperidone is in the benzisoxazole derivative class of atypical antipsychotics (in-
cluding risperidone, iloperidone and paliperidone) and acts in accordance with others in
the class [48]. While the full mechanism of atypical antipsychotics is yet to be fully real-
ized, common features of the class include affinity for dopamine D2 and serotonin 5-HT2A
receptors [51]. Unlike typical antipsychotics, atypicals, in general, have a higher ratio of
antagonism at 5-HT2A than D2 receptors and have varying effects on other receptors [51].
In addition to 5-HT2A and D2 antagonism, paliperidone has antagonistic effects at α1 and
α2 adrenergic and H1 histaminergic receptors [52]. It has no affinity for M1 cholinergic or
β adrenergic receptors [52]. Positron emission tomography has shown paliperidone to oc-
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cupy 70–80% of D2 receptors in striatal and temporal cortex with a median effective dose of
2.38 mg/day and 2.84 mg/day, respectively [53]. Despite being the major active metabolite,
paliperidone’s affinity profile does not equal that of risperidone—paliperidone has a lower
ratio of 5-HT2A/D2 antagonism, lower affinity for α1 and α2 receptors and higher affinity
for H1 receptors [54]. Paliperidone receptor antagonism has been demonstrated in rats to
affect serotonergic and noradrenergic signaling differently than risperidone in vivo [55].
Additionally, molecular signaling events following receptor binding have been shown to
be distinct when comparing paliperidone and risperidone [56]. Paliperidone also has been
demonstrated to induce mitochondrial protein expression changes in the prefrontal cortex
similar to lithium, suggesting it may have mood stabilizing properties [57]. The molecular
changes observed included increased proteins associated with receptor signaling, oxidative
phosphorylation, neurotransmitter release and synaptic plasticity [57].
6. Pharmacokinetics/Pharmacodynamics
Paliperidone ER is designed with an osmotically controlled-release system which
allows for continuous drug delivery after oral administration and no initial titration [48].
Paliperidone itself is insoluble in water with a volume of distribution of 487 L and it has an
oral bioavailability of 28% [48,51]. Paliperidone ER reaches maximal concentration (Cmax)
in 24 h and increases in Cmax and the area under the drug concentration vs time curve (AUC)
are observed after a high-fat or high-calorie meal [48,51]. Paliperidone ER demonstrates
dose-response proportional AUC and Cmax in the recommended dose range [48,51]. The
time to reach steady-state is 4–5 days and terminal half-life is 23 h [48,51].
The LAI paliperidone palmitate is deposited and slowly hydrolyzed to paliperidone
over time. The 1-month and 3-month injectable forms reach Cmax in a median time of
13 days and 33 days, respectively, and both have higher Cmax when a deltoid injection
is used rather than gluteal [49–51]. For this reason, the initial two doses are given in the
deltoid muscle to rapidly achieve therapeutic concentration [49,50].
Paliperidone is minimally metabolized by the cytochrome P450 2D6 and cytochrome
P450 3A4 enzymes; however, these are suggested to play a clinically irrelevant role over-
all [48,51]. Paliperidone is excreted 59% into urine unmetabolized and 11% into feces [48,51].
Divalproex sodium coadministration with paliperidone resulted in higher Cmax and AUC of
oral paliperidone [48]. Carbamazepine coadministration decreased paliperidone by increas-
ing renal clearance of paliperidone [48]. Renal impairment resulted in decreased clearance
of paliperidone by 32% in mild impairment (CrCl from 50 mL/min to <80 mL/min), 64%
in moderate impairment (CrCl from 30 mL/min to <50 mL/min) and 71% in severe impair-
ment (CrCl from 10 mL/min to <30 mL/min) [48]. Mild to moderate hepatic impairment
does not alter the plasma concentration of unbound paliperidone [48]. Effects of renal or
hepatic impairment have not been directly studied for the LAI paliperidone palmitate.
7. Clinical Studies: Safety and Efficacy
7.1. Safety and Efficacy
Many studies have explored the efficacy and safety of paliperidone in patients with
schizophrenia and/or schizoaffective disorder. Common measures of drug efficacy used
in these studies include the Positive and Negative Syndrome Scale (PANSS), the Clinical
Global Impression Severity (CGI-S) Scale, the Young Mania Rating Scale (YMRS), Hamilton
Depression Rating Scale 21-item version (HDRS-21) and the Personal and Social Perfor-
mance (PSP) Scale. Some studies also measured the time to relapse as a primary measure
of clinical efficacy. In these studies, paliperidone was generally well tolerated; however,
adverse effects were not uncommon and include headache, anxiety, insomnia, weight gain,
suicidal ideation, nasopharyngitis, UTI and extrapyramidal symptoms.
Bossie et al. extrapolated data from a multiphase schizoaffective disorder study
(NCT01193153) to examine the effect of paliperidone palmitate once-monthly injections
(PP1M) in patients with recent-onset (≤5 years since first psychiatric diagnosis; n = 206)
and chronic illness (>5 years; n = 461) versus placebo [58]. Multiple efficacy scales were
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utilized in their study, including the PANSS, CGI-S, PSP, YMRS and HAM-D-21. It was
found that both PP1M subpopulations displayed improvements in all scales used during
the open-label PP1M acute and stabilization phases, with greater improvement noted in
the recent onset subpopulation (p ≤ 0.022). Relapse rates were higher in the placebo group
compared to both PP1M subpopulations. In the recent onset subpopulation, the placebo
group had a relapse rate of 30% and the PP1M participants had a relapse rate of 10.2%
(p = 0.014; hazard ratio (HR): 2.8; 95% confidence interval (CI): 1.11–7.12; p = 0.029). In the
chronic illness subpopulation, the placebo group had a relapse rate of 35.5% and the PP1M
participants had relapse rate of 18.1% (p = 0.014; hazard ratio (HR): 2.8; 95% confidence
interval (CI): 1.11–7.12; p = 0.029). Treatment-emergent adverse effects (TEAEs) occurred in
over half of patients taking PP1M, with more noted in the chronic illness subpopulation
(65.1%) compared to the recent onset (56.8%) subpopulation. The most common adverse
effect was related to administration site conditions, such as pain. Other adverse effects
reported were headache, insomnia, suicidal ideation, weight gain, akathisia, drug-induced
parkinsonism, tremor and symptomatic prolactin related TEAEs, such as decreased libido
and amenorrhea [58].
Fu et al. conducted a double-blind, randomized study evaluating the effects of
paliperidone in 334 patients with schizoaffective disorder [59]. Paliperidone monother-
apy and adjunctive paliperidone therapy were compared to placebo for 15 months. They
found that PP1M significantly reduced the time to relapse for both treatment options
(p < 0.001). The relapse risk was 3.38 times greater in the placebo group compared to
PP1M monotherapy (p = 0.002) and 2.03 greater when compared to PP1M as adjunc-
tive therapy (p = 0.021). The overall risk of relapse was 2.49 times greater for placebo
(HR = 2.49; 95% CI: 1.55 to 3.99; p < 0.001), with an overall relapse rate of 33.5%. In contrast,
the PP1M groups had relapse rates of 15.2%. Using the PSP scale, the researchers found
that PP1M was superior to placebo in maintaining cognitive functioning. Common adverse
effects found in this study were increased weight, insomnia, headache, nasopharyngitis
and extrapyramidal symptoms [59].
Management of elderly patients with schizophrenia can be challenging, as they of-
ten have reduced liver and kidney function required to metabolize certain antipsychotic
medications. Paliperidone, the primary metabolite of risperidone, is thought to be less
likely influenced by changes in metabolism, leading to better outcomes in elderly patients
with schizophrenia, while reducing treatment-emergency adverse effects. This under-
standing prompted Suzuki et al. to study the efficacy and safety of switching patients
from risperidone to a pump-administered extended-release paliperidone formulation [60].
They enrolled 27 patients in their study, assigning 13 to the switch group and 14 to the
control group (i.e., did not change from risperidone to paliperidone). The PANSS scores
showed no significant difference between the two groups. This indicated, to the researchers,
that paliperidone works equally well as risperidone in managing schizophrenia. Primary
safety outcomes were evaluated using the Drug-induced Extrapyramidal Symptoms Scale
(DIEPSS), the Drug Attitude Inventory Scale and prolactin levels. DIEPSS scores and pro-
lactin levels had significantly greater reductions from baseline in the paliperidone group
and the Drug Attitude Inventory Scale showed that elderly patients had more favorable
views on paliperidone than risperidone. Additionally, patients in the paliperidone group
required less biperiden when compared to the control group when EPS symptoms did
arise even with similar risperidone-equivalent doses. The researchers thus concluded that
paliperidone might result in superior safety and patient satisfaction in elderly patients [60].
Medication noncompliance is a major barrier for schizophrenia and schizoaffective
disorder maintenance therapy. Like many patients with chronic medical conditions, pa-
tients with schizophrenia and schizoaffective disorder may not always comply with their
antipsychotic medications because they have difficulty with daily oral therapy [61]. There-
fore, longer-acting formulations can provide one means of optimized care for patients
with chronic noncompliance problems. Hargarter et al. conducted a prospective, mul-
ticentral, open-label, 6-month study to see how patients with schizophrenia who failed
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oral antipsychotic responded to the LAI formulation paliperidone palmitate [62]. Nearly
70% of the 212 patients enrolled in this study had clinical improvement in psychotic symp-
toms, as demonstrated by ≥30% improvement in mean PANSS scores (p < 0.0001) [61].
Another study, by Mauri et al., explored the effectiveness of switching to flexible doses of
paliperidone ER from other antipsychotic regimens [63]. A total of 110 of the 133 patients
were analyzed after the application of exclusion criteria such as inability to swallow oral
medication. They found that patients had improvement in multiple scoring measures,
including the PANSS, PSP and CGI-S scales when using paliperidone ER [63]. Furthermore,
patients who have failed therapy on other long-acting or commonly used depot therapies
can benefit from paliperidone palmitate injections. Schreiner et al. demonstrated that
patients who switched from conventional depot antipsychotics (n = 174) or risperidone
long-acting medications (n = 57) to paliperidone once monthly had significant reductions
in mean PANSS scores, as well as improvement in symptom severity measured by the
CGI-S [64]. The above studies also found that paliperidone formulations are generally well
tolerated. Taken together, these studies support the notion that patients with schizophre-
nia and schizoaffective disorder can be better managed and suffer less from psychosis
when taking paliperidone as a long-acting medication over other treatment modalities that
indirectly promote noncompliance or had treatment failure on a different regimen.
Paliperidone injections can also be given once every three months. This formulation
may be beneficial in preventing relapse of symptoms in schizophrenic and schizoaffective
patients. Savitz et al. studied the efficacy and safety of paliperidone palmitate 3-month
(PP3M) formulations for patients with schizophrenia in a randomized, multicenter, double-
blind, noninferiority study [65]. PP3M was compared directly to the more conventional
once-monthly paliperidone injections. Kaplan–Meier estimates showed that relapse rates
were similar in those receiving PP3M and PP1M. Additionally, the pharmacokinetics
between PP3M and PP1M were nearly the same, with no clinically relevant differences
observed. The side effect profiles of the formulations were also similar, with weight gain
being the most common treatment-emergent adverse effect [65].
Recent advancements in psychiatric research has discovered that levels of brain-
derived neurotrophic factor (BDNF) could correlate with neuroprotection in schizophrenia,
with higher levels indicating better outcomes [66]. A study by Wu et al. sought to quan-
tify positive outcomes using antipsychotic treatment with risperidone or paliperidone
with serum levels of BDNF and N400 latency and amplitudes. N400, an event-related
brain potential component, recordings were performed to quantify cognitive functioning
in schizophrenic patients. Both groups had increases in serum BDNF levels (p < 0.01)
after 12 weeks of treatment, with no significant difference between the BDNF levels in
the two treatment groups. N400 amplitudes also increased in both groups after treatment
(p < 0.01). However, N400 latency periods were shorter with paliperidone therapy, com-
pared to risperidone (p < 0.01), possibly indicating that paliperidone therapy leads to faster
benefits in cognitive improvement. The researchers also used PANSS scores in their study,
finding that it was significantly reduced in both groups (p < 0.01) after treatment [66]. One
drawback of this study is that serum BDNF levels may be inferior to CNS BDNF measure-
ments. Another drawback was the sample size of this study was small; larger samples will
be needed in the future when using BDNF levels as a primary outcome. However, this
study provides further support for paliperidone as an effective treatment for schizophrenia.
7.2. Comparative Studies
Researchers have also directly compared paliperidone to other treatment options in
the management of schizophrenia and schizoaffective disorder. Alphs et al. compared
once-monthly paliperidone palmitate to daily oral antipsychotic therapy in patients with
schizophrenia using a randomized clinical trial [67]. Time to first treatment failure was the
primary endpoint. This was defined by arrest/incarceration, hospitalization in a psychiatry
ward, increased utilization of psychiatric services, suicide, or treatment discontinuation
for reasons such as safety, tolerability, or efficacy. To measure time to treatment failure, the
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Kaplan–Meyer method was utilized. Of the 450 patients enrolled in the study, 444 patients
were included in an intent-to-treat analysis. They found that time to first treatment failure
was significantly delayed in the paliperidone palmitate group. Over 15 months, the
paliperidone group had treatment failure rates of 39.8%, whereas the oral antipsychotic
group had treatment failure rates of 53.7%. The most common reasons were arrests and
psychiatric hospitalizations for both groups. Common adverse effects in the paliperidone
group were injection site pain, insomnia, weight gain, akathisia and anxiety [67].
Long-acting intramuscular versions of paliperidone have also been compared to
long-acting haloperidol in the management of schizophrenia and schizoaffective disorder.
McEvoy et al. found no significant difference between the efficacy of haloperidol and
paliperidone [68]. Stroup et al. conducted a similar study that also demonstrated no
significant difference between the two treatment options. However, Stroup et al. also
found that haloperidol was associated with significantly longer time to efficacy failure
in young patients (ages 18–45), whereas paliperidone was associated with significantly
longer time to efficacy failure in older patients (ages 46–65). Stroup et al. noted that
these age-related discrepancies warrant further investigation of these drugs in clinical
practice [69]. Besides age, reasons to use one or the other may rely on side effect profiles.
Prolactin levels and weight were demonstrated to increase more with paliperidone therapy
compared to haloperidol. However, haloperidol was associated with a greater risk of
extrapyramidal side effects, including akathisia [68,69]. Cost effectiveness should also be
taken into consideration when choosing between haloperidol and paliperidone. A study by
Rosenheck et al. concluded that paliperidone had slightly greater benefits in maintenance
therapy of schizophrenia, but these benefits do not justify its high costs when haloperidol
is markedly cheaper from the perspective of the healthcare system [39]. However, a
first-generation antipsychotic is generally not preferred over second generations in the
management of schizophrenia and schizoaffective disorder. Therefore, physicians must
carefully consider the above findings when the decision to use a long-acting injectable is
being made.
Aripiprazole is a third-generation antipsychotic that has demonstrated efficacy in treat-
ing schizophrenia and schizoaffective disorder. Its unique mechanism of action prompted
Naber et al. to compare it to paliperidone. The researchers used the Heinrichs–Carpenter
Quality-of-Life Scale (QLS) to compare once-monthly LAI formulations of aripiprazole
to paliperidone in a 28-week randomized, noninferiority, rater-blinded, head-to-heady
study. Aripiprazole was found to be superior to paliperidone in this regard [70]. De-
spite this, paliperidone is still a good option to consider when treating schizophrenia and
schizoaffective disorder. This has been demonstrated numerous times, especially when
compared to oral antipsychotics. Alphs et al. found that paliperidone palmitate injections
reduce the risk of treatment failure when compared to oral antipsychotics, especially in
recent-onset schizophrenia [71]. Another study by Alphs, Mao, Starr and Benson replicated
these findings [72]. When compared to oral antipsychotics, paliperidone is more effective
in delaying median time to treatment failure and reduces the number of treatment failures
and psychiatric institutionalizations [72].
These studies, as well as numerous others, demonstrate that paliperidone is an effec-
tive therapeutic option in treating patients with schizophrenia and schizoaffective disorder.
It is generally well tolerated, with weight gain being a common side effect. A question
physicians often want to know is the type of formulation to give. The above works support
that long-acting formulations are associated with better outcomes in schizophrenic and
schizoaffective patients. When deciding between extended release tablets and long-acting
injectables, physicians must take into consideration a patient’s personal preference. How-
ever, research by Levitan et al. suggests that paliperidone once-monthly injections have
shown greater benefits when compared to extended release tablets, especially early on in
the disease process [73]. This drug should be considered in the management of schizophre-
nia and schizoaffective disorder. Table 1 is a summary of the clinical studies discussed in
this section and Table 2 is a summary of the comparative studies.
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Table 1. Clinical efficacy and safety.
Author (Year) Groups Studied andIntervention Results and Findings Conclusions
Bossie et al. (2017)
[58]
Patients with chronic (n = 461)
or recent onset (n = 206)
schizoaffective disorder were
treated with a 13-week open
label acute treatment with
PP1M, then 12-weeks
stabilization with PP1M, then
a 5-month double-blind
relapse prevention, where
patients were randomized to
continue PP1M or withdrawal
to placebo.
Both subpopulations showed significant
improvement in mean psychotic, mood and
function scores (p ≤ 0.022). Relapse rates
were higher with placebo than PP1M in the
recent onset subpopulation (30% vs. 10.2%,
p = 0.014) and the chronic illness
subpopulation (35.5% vs. 18.1%, p = 0.001).
The percentage of patients meeting all
stabilization criteria was higher in the recent
onset group (70.4%) than the chronic illness
group (60%), p = 0.010.
Paliperidone is useful in
managing
schizoaffective disorder.
It is especially beneficial
in treating patients with
recent onset disease and
should be utilized
clinically.
Fu et al. (2015) [59]






treatment vs. placebo, first
with a 13-week open-label
phase, then a 12-week
stabilization period, followed
by a 15-month double-blind,
relapse prevention phase.
Relapse risk was 2.49 times greater in placebo
vs paliperidone once-monthly (p < 0.001).
Paliperidone delays the time to relapse when
added onto other medications regimens. The
placebo group had a 3.38 times greater
relapse risk than paliperidone monotherapy
and a 2.03 times greater relapse risk than







Paliperidone can be used
as either a monotherapy
or adjunctive therapy in
patients with
schizoaffective disorder.
Suzuki et al. (2013)
[60]
A total of 27 inpatients with
schizophrenia were switched
to paliperidone therapy
(n =13) or maintained on
risperidone (n = 14) and
results were obtained at
12 weeks.
The PANSS score was the primary efficacy
outcome measure; there was no significant
difference between the paliperidone and
risperidone groups. DIEPSS and prolactin
levels were significantly decreased from
baseline in the paliperidone group compared
to the risperidone group (−3.1 vs. −0.5,
respectively, p = 0.0002). Prolactin levels
decreased more in the paliperidone group
from baseline than the risperidone group
(p = 0.04). Less biperiden was needed to
manage EPS symptoms in the paliperidone
group (p = 0.006). Patients reports more
favorable views on paliperidone than
risperidone using the Drug-Attitude











A total of 212 patients with




open-label, 6-month trial with
once-monthly
paliperidone injections.
Two-thirds of patients receiving paliperidone
injections met the criteria for clinical
response (≥30% improvement in mean
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Table 1. Cont.
Author (Year) Groups Studied andIntervention Results and Findings Conclusions
Mauri et al. (2015)
[63]
A total of 133 schizophrenic
patients switched to
paliperidone extended release
PO and followed for 13-weeks.
Patients were assessed at day 0,
14 days, 42 days and 91 days.
PANNS score decreased (from
88.98 ± 10.09 to 66.5 2 ± 16.29, p < 0.001).
PSP and CGI-S scores also decreased
(p < 0.001). Significant differences in these
scores were found starting at week 2 and
maintained throughout the trial.
Paliperidone ER shown to
be efficacious. It can be
considered in patients
with schizophrenia.







switched from RLAT or oral
antipsychotics (n = 231) to
PP1M.
PANSS total score from baseline to
last-observation-carried-forward were
significantly reduced for both groups (from
−7.5 to 10.6, p ≤ 0.01 (BL to LOCF EP)).
CGI-S scores also improved in the study







can be prescribed if other
therapies have failed.
Savitz et al. (2016)
[65]
Double blind, parallel group,
multicenter, phase-3 study
compared PP3M to PP1M in
1016 patients with
schizophrenia in a 3-week
screening period, 17-week
open label phase; clinically
stable patients were
randomized to PP3m or PP1M
for 48-week double-blind
phase.
PP3M was non-inferior to PP1M with
similar relapse rates in both groups (PP3M
n = 37, 8%, PP1M n = 45, 9%); difference in
relapse free rate (measured via
Kaplan–Meier criteria) was 1.2%. No
clinically relevant pharmacokinetic
differences observed. Safety profiles
similar, with weight gain being the most
common side effect (double blind phase;
21% each).
PP3M showed similar
efficacy as PP1M in
preventing relapse in
patients with
schizophrenia. PP3M is a










both groups received 17-week
open-label PP1M stabilization,
followed by two subsequent
studies. Study A: patients
randomized to PP1M or PP3M
in a 48-week double blind
treatment phase. Study B:
patients entered a 12-week
open label phase comparing
PP3M to placebo.
Study A: relapse free percentage was
similar in Latin America and ROW patients
using PP1M or PP3M. Study B: median
time-to-relapse was not significantly
different between the placebo or PP3M
Latin American patients. For the ROW
group, median time-to-relapse for the
placebo subgroup was 395 days and not
estimable for the PP3M subgroup.
There is no significant
difference in using PP1M









Wu et al. (2018) [66]
A total of 94 patients with
first-time episodes of
schizophrenia were randomly
divided into risperidone or
paliperidone treatment groups
for 12 weeks. Serum BDNF
levels, the latency and
amplitude of N400 and
PANNS scores were compared
before and after treatment in
the two groups.
Serum BDNF increased in both groups, no
significant difference was found between
the groups before and after treatment.
After treatment, N400 amplitudes
increased (from 4.73 ± 2.86 µv and
4.51 ± 4.63 µv to 5.34 ± 4.18 µv and
5.52 µv, p < 0.01). N400 latencies were
shortened in the paliperidone group (from
424.13 ± 110.42 ms to 4.7.41 ± 154.59 ms,
p < 0.05) under incongruent conditions.
Paliperidone and
risperidone could increase
serum BDNF levels in
schizophrenic patients with




drugs can improve the
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Table 2. Comparative studies.
Author (Year) Groups Studied andIntervention Results and Findings Conclusions
Alphs et al. (2018)
[71]
A 15 month randomized
multicenter study of adults
with schizophrenia and a
history of incarceration;
450 patients assigned to PP1M
(n = 230) or PO antipsychotics
daily (n = 220).
PP1M associated with significant delay in
time to first treatment failure when
compared to PO antipsychotics (HR = 1.43;
95% CI = 1.09–1.88; log rank p = 0.011). The
failure rate for PP1m was 39.8%; 53.7% was
the treatment failure rate in the oral
antipsychotic group. Treatment failure was
commonly due to arrest/incarceration (21.2%
in PP1M; 29.4% in PO) and psychiatric
hospitalizations (8.0% in PP1M; 11.9% in PO).
The five most common TEAEs for PP1M
were injection site pain, insomnia, weight
gain, akathisia and anxiety.
Time to treatment failure
was greater in the PP1M
group compared to the
PO antipsychotic
daily group.
McEvoy et al. (2014)
[68]
A total of 311 randomized
schizophrenic or
schizoaffective patients aged
18–65 placed in paliperidone
palmitate (n = 157) or
haloperidol decanoate
(n = 154) followed for
24 months.
No statistically significant difference in rate
of efficacy failure for paliperidone compared
to haloperidol was found (HR = 0.98;
95%CI = 0.65–1.47). Paliperidone patients
gained weight; haloperidol patients lost
weight on average. Paliperidone increased
prolactin levels, whereas haloperidol







Stroup et al. (2019)
[69]
A total of 311 patients meeting
the criteria for schizophrenia
or schizoaffective disorder
were randomly assigned to
double-blinded treatment
with haloperidol decanoate or
paliperidone palmitate and
followed for two years.
Age was correlated with different outcomes
in different age groups. Young patients (ages
18–45) in the haloperidol group had longer














once-monthly treatment for at
least 24 months.
Paliperidone had 0.027 greater Quality
Adjusted Life Years over 18 months (p = 0.03),
with greater quarterly medical costs including
inpatient and outpatient treatment of USD
21,000/quarter. There is a 0.98 probability of
greater cost-effectiveness when using
haloperidol instead of paliperidone calculated
using the Net Health Benefits analysis.





even though it may be
superior in managing
symptoms.
Naber et al. (2015)
[70]




was conducted in 295 adult
patients aged 18–60 years old
with schizophrenia.
Statistically significant least squares mean
difference in change from baseline to week 28
QLS total score demonstrated that
aripiprazole is superior to paliperidone.
Other ratings utilized gave further evidence
to support this finding, including significant





efficacy and safety when
compared to
paliperidone.
Alphs et al. (2015)
[67]
Schizophrenic patients with a






Treatment failure hazard ratios for oral
antipsychotics versus paliperidone were
1.73 (0.87–3.45; p = 0.121) for recent onset




risk of treatment failure
compared to oral
antipsychotic regimens.
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Table 2. Cont.




Schizophrenic patients with a




injections (78–243 mg) or daily
oral antipsychotic therapy in a
15-month prospective study.
Mean cumulative function of treatment
failure events differed significantly in favor
of paliperidone (p = 0.007) over oral
antipsychotics (p = 0.005).
Paliperidone is superior
to oral antipsychotics in
delaying median time to
treatment failure.
Levitan et al. (2016)
[73]
Patients with schizophrenia
were assigned to either
extended release or injectable
paliperidone once-monthly
formulations and evaluated at
8 and 40 weeks.
At 8 weeks, PSP worsening, relapse, PANSS
worsening and hospitalizations were
significantly more associated with extended
release paliperidone. At 40 weeks, relapse,
PANSS, hospitalizations and CGI-S scales
favored PP1M; however, these results were
not significant. At both time intervals, safety
outcomes were not significant amongst the
groups.





earlier in the disease.
8. Conclusions
The use of atypical antipsychotics remains central in the long-term treatment of
schizophrenia and schizoaffective disorder. Relatively new as a long-acting injectable
antipsychotic, paliperidone is of particular interest in promoting treatment adherence
and reducing symptoms over longer periods of time. The 3-month paliperidone palmi-
tate is currently the longest-acting antipsychotic available for use in schizophrenia and
schizoaffective disorder. Its mechanism of action is similar to most other atypical antipsy-
chotics, antagonizing D2 and 5-HT1A receptors. It has been shown to be effective and safe,
compared to placebo, in the treatment of these disorders by various scoring measures in
multiple studies. Paliperidone LAI is a favorable choice in patients who have failed oral
antipsychotic regimens. Although some studies demonstrated slightly reduced efficacy
compared to other antipsychotics, paliperidone has demonstrated reduced risk of treatment
failure over time. Compared to its parent compound risperidone, paliperidone may be
more favorable due to similar efficacy, increased safety and increased patient satisfaction.
Paliperidone is not significantly affected by liver and renal function and is thus a good
choice for consideration in patients with decreased hepatic or renal function. Further stud-
ies are required to evaluate combination long-term therapies and daily coadministration of
other antipsychotics for schizophrenia or schizoaffective disorder.
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